Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: A meta-analysis

Treatment options in patients with metastatic gastric cancer: Current status and future perspectives

(2014) Ahmet Bilici   WORLD JOURNAL OF GASTROENTEROLOGY

A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer

(2013) Dingzhi Huang et al.   EUROPEAN JOURNAL OF CANCER

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

(2013) Yasuhide Yamada et al.   LANCET ONCOLOGY

S-1 for the treatment of gastrointestinal cancer

(2012) Taroh Satoh et al.   EXPERT OPINION ON PHARMACOTHERAPY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pharmacotherapy for pediatric soft-tissue sarcomas

(2011) Michela Casanova et al.   EXPERT OPINION ON PHARMACOTHERAPY

Therapeutic management of breast cancer in the elderly

(2011) Simon Spazzapan et al.   EXPERT OPINION ON PHARMACOTHERAPY

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

(2010) Jaffer A. Ajani et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

(2010) Kei Muro et al.   LANCET ONCOLOGY

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials

(2009) Lidan Liu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

(2009) Narikazu Boku et al.   LANCET ONCOLOGY

Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas

(2008) T. Shirasaka   JAPANESE JOURNAL OF CLINICAL ONCOLOGY